Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction

The management of locally advanced head and neck squamous cell carcinoma (HNSCC) with Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), achieves only moderate response rates, and clinical trials that evaluated EGFR-blockade with tyrosine kinase inhibitors (TKI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Job, Sylvie, de Reyniès, Aurélien, Heller, Betty, Weiss, Amélie, Guérin, Eric, Macabre, Christine, Ledrappier, Sonia, Bour, Cyril, Wasylyk, Christine, Etienne-Selloum, Nelly, Brino, Laurent, Gaiddon, Christian, Wasylyk, Bohdan, Jung, Alain C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627901/
https://www.ncbi.nlm.nih.gov/pubmed/31181806
http://dx.doi.org/10.3390/cancers11060795

Ejemplares similares

Ejemplares similares